Optimi Health (TSE:OPTI) has released an update.
Optimi Health Corp. has received three export permits from Health Canada to begin supplying its GMP-compliant MDMA and psilocybin capsules to Australia, marking the company’s first commercial venture into the country. These capsules are intended for the treatment of PTSD and Treatment-Resistant Depression under Australia’s Authorised Prescriber Scheme. The move follows Australia’s reclassification of these substances for regulated medical use and is seen as a significant step in the global supply of psychedelic-assisted therapies.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
